<unk>  is used to treat type 2 diabetes mellitus as an add-on to metformin, a biguanide, or a combination of metformin and a sulfonylurea, or thiazolidinediones such as pioglitazone. A 2011 Cochrane review showed a HbA1c reduction of 0.20% more with<unk>  2mg compared to insulin glargine,<unk>  10µg twice daily, sitagliptin and pioglitazone.<unk> , lead to greater weight loss than glucagon-like peptide analogues. Due to shorter duration of studies, this review did not allow for long-term positive or negative effects to be assessed. It is also being evaluated for use in the treatment of Parkinson's disease. The medication is injected subcutaneously twice per day using a filled pen-like device (Byetta), or on a weekly basis with either a pen-like device or conventional syringe (Bydureon). The abdomen is a common injection site.
Exenatide
Liraglutide
Linagliptin
Pioglitazone
Insulin degludec
Rosiglitazone
Canagliflozin
Vildagliptin